AstraZeneca wins UK cost approval for longer use of heart drug
 

AstraZeneca wins UK cost approval for longer use of heart drug
LONDON (Reuters) - Long term use of AstraZeneca's blood thinner Brilinta has been recommended as a cost-effective option for treating patients after a heart attack, Britain's healthcare cost watchdog NICE said on Friday.http://feeds.feedburner.com/~ff/reut...?d=yIl2AUoC8zA http://feeds.feedburner.com/~ff/reut...Zs:F7zBnMyn0Lo http://feeds.feedburner.com/~ff/reut...Zs:V_sGLiPBpWU
http://feeds.feedburner.com/~r/reute...~4/XyJegBqB3wQ